Nectar Lifesciences Limited , a prominent player in the pharmaceutical industry, has made a significant stride in improving its financial health. The company has announced the complete repayment of its secured debt, along with accrued interest, to its consortium lenders.

Key Highlights

• Debt Repayment: Nectar Lifesciences has fully repaid its secured debt to consortium lenders.
• Amount Settled: The total consortium charge satisfied amounts to INR 1,338.35 crore.
• Assets Released: The repayment releases both movable and immovable assets, including current assets, from the consortium charge.
• Security Trustee: SBICAP Trustee Company Limited acted as the Security Trustee for the lenders.
• Official Registration: The satisfaction of charge has been registered with the Registrar of Companies, Punjab and Chandigarh on October 22, 2025.

Financial Implications

This debt clearance marks a pivotal moment for Nectar Lifesciences, potentially leading to:

1. Improved financial flexibility
2. Enhanced creditworthiness
3. Reduced interest burden
4. Greater operational freedom with unencumbered assets

Regulatory Compliance

The company has duly informed the National Stock Exchange of India Limited and BSE Limited about this development, in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Company's Statement

Sanjaymohan Singh Rawat, Company Secretary & Compliance Officer of Nectar Lifesciences Limited, confirmed the development in an official communication to the stock exchanges. The statement emphasized that the satisfaction of charge has been "duly filed and registered on October 22, 2025, with the Registrar of Companies, Punjab and Chandigarh, Ministry of Corporate Affairs, Government of India, in accordance with the provisions of Chapter VI of the Companies Act, 2013."

This strategic move by Nectar Lifesciences to clear its substantial secured debt signifies a strong commitment to financial prudence and may position the company for more robust growth in the coming years. Investors and market watchers will likely keep a close eye on how this debt clearance translates into the company's operational and financial performance in the subsequent quarters.

Nectar Lifesciences Ltd. has announced a further extension to the completion date of its planned sale to Ceph Lifesciences Private Limited. The company has set a new target date of November 19, 2025, marking the third postponement of this significant corporate action.

Timeline of Extensions

The company has provided the following timeline for the completion of the sale:

Details of the Transaction

The transaction involves a slump sale of Nectar Lifesciences' business of manufacture, distribution, marketing, and sale of active pharmaceutical ingredients and formulations to Ceph Lifesciences Private Limited.

Regulatory Compliance

Nectar Lifesciences has made this announcement in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (LODR Regulations).

Shareholder Approval

The company had previously sought and received shareholder approval for this transaction. An Extraordinary General Meeting (EGM) was held on August 4, 2025, following notices dated July 7, 2025, and an addendum dated July 23, 2025.

Impact and Outlook

While the repeated extensions might raise questions about the progress of the deal, both Nectar Lifesciences and Ceph Lifesciences Private Limited have mutually agreed to this latest extension. The company has not provided specific reasons for the delay in its regulatory filing.

Investors and stakeholders will likely be watching closely for any further updates on this transaction, as it represents a significant change in Nectar Lifesciences' business structure. The completion of this sale could have substantial implications for the company's future operations and financial position.

Stakeholders are advised to refer to official company communications and regulatory filings for the most accurate and up-to-date information regarding this corporate action.